Table 2.

Primary and Secondary Outcomes by Treatment Group

Fidaxomicin (n = 38)Vancomycin (n = 200)Total (N = 238)
Primary outcome: compositea4 (10.5)38 (19.0)42 (17.6)
Secondary outcomes
 Clinical failure2 (5.3)4 (2.0)6 (2.5)
 Relapse
  30 db1 (2.9)25 (13.4)26 (11.7)
  90 dc2 (5.9)14 (8.6)16 (8.2)
  Total3 (8.6)39 (20.9)42 (18.9)
 Death related to CDI1 (2.6)9 (4.6)10 (4.3)
 Other causes of death5 (13.2)7 (3.5)12 (5.0)
Fidaxomicin (n = 38)Vancomycin (n = 200)Total (N = 238)
Primary outcome: compositea4 (10.5)38 (19.0)42 (17.6)
Secondary outcomes
 Clinical failure2 (5.3)4 (2.0)6 (2.5)
 Relapse
  30 db1 (2.9)25 (13.4)26 (11.7)
  90 dc2 (5.9)14 (8.6)16 (8.2)
  Total3 (8.6)39 (20.9)42 (18.9)
 Death related to CDI1 (2.6)9 (4.6)10 (4.3)
 Other causes of death5 (13.2)7 (3.5)12 (5.0)

Abbreviation: CDI, Clostridioides difficile infection.

Data are presented as No. (%).

aComposite outcome: clinical failure, relapse at 30 days, and death related to CDI.

bAfter exclusion of patients who died (n = 222).

cAfter exclusion of patients who had clinical failure, died, or had 30-day relapse (n = 196).

Table 2.

Primary and Secondary Outcomes by Treatment Group

Fidaxomicin (n = 38)Vancomycin (n = 200)Total (N = 238)
Primary outcome: compositea4 (10.5)38 (19.0)42 (17.6)
Secondary outcomes
 Clinical failure2 (5.3)4 (2.0)6 (2.5)
 Relapse
  30 db1 (2.9)25 (13.4)26 (11.7)
  90 dc2 (5.9)14 (8.6)16 (8.2)
  Total3 (8.6)39 (20.9)42 (18.9)
 Death related to CDI1 (2.6)9 (4.6)10 (4.3)
 Other causes of death5 (13.2)7 (3.5)12 (5.0)
Fidaxomicin (n = 38)Vancomycin (n = 200)Total (N = 238)
Primary outcome: compositea4 (10.5)38 (19.0)42 (17.6)
Secondary outcomes
 Clinical failure2 (5.3)4 (2.0)6 (2.5)
 Relapse
  30 db1 (2.9)25 (13.4)26 (11.7)
  90 dc2 (5.9)14 (8.6)16 (8.2)
  Total3 (8.6)39 (20.9)42 (18.9)
 Death related to CDI1 (2.6)9 (4.6)10 (4.3)
 Other causes of death5 (13.2)7 (3.5)12 (5.0)

Abbreviation: CDI, Clostridioides difficile infection.

Data are presented as No. (%).

aComposite outcome: clinical failure, relapse at 30 days, and death related to CDI.

bAfter exclusion of patients who died (n = 222).

cAfter exclusion of patients who had clinical failure, died, or had 30-day relapse (n = 196).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close